tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Fractyl Health initiated with a Buy at Ladenburg

Ladenburg initiated coverage of Fractyl Health (GUTS) with a Buy rating and $3.60 price target Fractyl is “advancing a differentiated approach to obesity” through its Revita duodenal mucosal resurfacing system, which has a “clearly defined” clinical development pathway, the analyst tells investors. The REMAIN-1 study will deliver initial readouts in late 2025, followed by pivotal six-month data from the 315-patient trial in the second half of next year, giving Fractyl multiple catalysts into 2026, the analyst added.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1